thiazoles has been researched along with quinazolines in 134 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (4.48) | 18.7374 |
| 1990's | 5 (3.73) | 18.2507 |
| 2000's | 43 (32.09) | 29.6817 |
| 2010's | 76 (56.72) | 24.3611 |
| 2020's | 4 (2.99) | 2.80 |
| Authors | Studies |
|---|---|
| Timmermans, PB; Van Zwieten, PA | 1 |
| Abd el-Samii, ZK; el-Feky, SA | 1 |
| Kubo, K; Nomoto, Y; Ohno, T; Takai, H | 1 |
| de Chaffoy de Courcelles, D | 1 |
| Jönsson, NA; Mikiver, L; Selberg, U | 1 |
| Ebata, M; Miyazaki, K; Otsuka, H | 1 |
| Baruth, HW; Carson, M; LeMahieu, RA; Welton, AF; Yaremko, B | 1 |
| Betit-Yen, K; Gitterman, CO; Lee, G; Luell, S; Prendergast, JS; Skipski, VP; Stock, CC | 1 |
| el-Feky, SA | 1 |
| Barnes, PJ; Giembycz, MA; Kelly, JJ | 1 |
| Agarwal, D; Bharadvaja, A; Errington, W; Jain, SC; Kumar, R | 1 |
| Abdel-Gawad, SM; El-Gaby, MS; Ghorab, MM | 2 |
| Bennett, GA; Georgiev, VS; Radov, LA; Trusso, LA | 1 |
| el-Sherbeny, MA | 1 |
| Alfranca, A; Aragonés, J; Jones, DR; Landázuri, MO; Martin, S; Mérida, I; San Juan, MA; Vara, A; Vidal, F | 1 |
| Carrillo, AJ; Guarro, J | 1 |
| Bouregeois, NM; Corbett, TH; Crantz, B; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Polin, L; White, K | 1 |
| Eppinger, E; Meinhardt, G; Schmidmaier, R | 1 |
| El-Bendary, ER; Gineinah, MM; Nasr, MN | 1 |
| Hussar, DA | 2 |
| Capilla, J; Guarro, J; Javier Pastor, F; Ortoneda, M; Pujol, I | 1 |
| Bally, MB; Chia, S; Denyssevych, T; Dragowska, WH; Gelmon, K; Masin, D; Wallis, AE; Warburton, C; Yan, H | 1 |
| Huang, WJ; Kan, SF; Lin, LC; Wang, PS | 1 |
| Fujiwara, M; Ishikawa, H; Nakayama, M; Ohtsuka, M; Satoh, H; Sekizawa, K | 1 |
| Fernández-Torres, B; Guarro, J; Lazéra, Mdos S; Trilles, L; Wanke, B | 1 |
| El-Bendary, ER; Goda, FE; Maarouf, AR | 1 |
| Bertorelli, R; Forlani, A; Fredduzzi, S; Grilli, M; Grzelak, ME; Guthrie, DH; Higgins, GA; Hodgson, RA; Hunter, JC; Lu, SX; Nicolussi, E; Parker, EM; Pond, AJ; Reggiani, A; Varty, GB | 1 |
| Binch, HM; Kay, DP; Li, P; Patel, SR; Pierce, AC; ter Haar, E | 1 |
| Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Oka, M; Soda, H; Takemura, M; Tsurutani, J; Yabuuchi, H; Yasunaga, M | 1 |
| Hough, LB; Lu, Q; Montero, MJ; Nalwalk, JW; Shan, Z; Svokos, K; Wentland, MP | 1 |
| Han, SY; Kim, BT; Lee, WG; Min, YK; Park, SS | 1 |
| de Lera, AR; Gaudon, C; Germain, P; Gronemeyer, H; Iglesias, B; Pereira, R | 1 |
| Laufer, S; Wagner, G | 1 |
| Davis, DA; Hussain, M; Li, Y; Sarkar, FH; Sarkar, SH | 1 |
| Brightwell, S; Brown, E; De Savi, C; Dousson, C; Germain, H; Green, S; Heaton, SP; Heron, N; Hill, GB; Johnson, T; Jung, FH; Keen, NJ; Lambert-van der Brempt, C; Lohmann, JJ; Mortlock, AA; Odedra, R; Pasquet, G; Renaud, F; Roberts, N; Thompson, K; Warin, N; Wedge, SR; Wilkinson, RW | 1 |
| Akaza, H; Hattori, K; Iida, K; Joraku, A; Oyasu, R; Tsukamoto, S | 1 |
| Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M | 1 |
| Bartlett, MC; Clarke, DM; Loo, TW; Wang, Y | 1 |
| Besson, T; Blairvacq, M; Léger, B; Logé, C; Lozach, O; Meijer, L; Robert, JM; Testard, A; Thiéry, V | 1 |
| Alves, SH; Azevedo, AC; Boff, E; Da Matta, DA; Guarro, J; Loreto, ES; Santurio, JM | 1 |
| Million, RP | 1 |
| Gautschi, O; Lee, D | 1 |
| Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Kendrew, J; Kettle, JG; Klinowska, T; Ogilvie, DJ; Pearson, SE; Williams, EJ; Wilson, I | 1 |
| Curtiss, FR | 1 |
| Cano, J; Gené, J; Gilgado, F; Guarro, J; Serena, C | 1 |
| Katakura, K; Kido, Y; Kita, K; Matsumoto, J; Miyoshi, H; Nonaka, N; Oku, Y; Sakamoto, K; Shinjyo, N; Yagi, K; Yamamoto, N | 1 |
| Allen, DA; Baskaran, S; Bui, M; Elling, RA; Flanagan, WM; Fung, AD; Hanan, EJ; Harris, S; Heumann, SA; Hoch, U; Jacobs, JW; Lam, J; Lawrence, CE; Lew, W; McDowell, RS; Nannini, MA; O'Brien, T; Oslob, JD; Romanowski, MJ; Shen, W; Silverman, JA; Sopko, MM; Tangonan, BT; Teague, J; Yoburn, JC; Yu, CH; Zhong, M; Zimmerman, KM | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Saad, F | 1 |
| Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Tao, LY; Wang, F; Yan, YY | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Yamada, Y; Yoshida, T | 1 |
| Clynes, M; McMahon, G; O'Connor, R; Roche, S | 1 |
| Ayuso-Sacido, A; Boockvar, JA; García-Verdugo, JM; Holland, EC; Kapoor, GS; Kratovac, S; Moliterno, JA; O'Rourke, DM; Roy, NS | 1 |
| Li, S; Wang, C; Wang, MW | 1 |
| Klein, RQ; Lok, W; Saif, MW | 1 |
| Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G | 1 |
| Goldani, LZ; Pasqualotto, AC; Thiele, KO | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Bonde, CG; Gaikwad, NJ; Peepliwal, A | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 2 |
| Dempke, W; Zippel, R | 1 |
| Merchant, NB; Nagaraj, NS; Washington, MK | 1 |
| Egloff, AM; Grandis, JR | 1 |
| Sheng, CQ; Wang, SZ; Zhang, WN | 1 |
| Türel, O | 1 |
| Auld, DS; Bougie, JM; Maloney, DJ; Misteli, T; Mott, BT; Nguyen, DT; Rosenthal, AS; Shen, M; Tanega, C; Thomas, CJ | 1 |
| Eadens, M; Messersmith, W; Puls, LN | 1 |
| Geoerger, B; Leblond, P | 1 |
| Criscione, JM; Jun, L; Lavik, EB; Robinson, R; Tsai, JC; Viviano, SR; Williams, CA | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Bareford, MD; Cruickshanks, N; Dai, Y; Dent, P; Grant, S; Hamed, HA; Hubbard, N; Mitchell, C; Tang, Y; Tye, G; Yacoub, A | 1 |
| Caci, E; Esposito, AI; Galietta, LJ; Pedemonte, N; Pfeffer, U; Sondo, E; Tomati, V | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Lo Nigro, C; Merlano, M; Milano, G; Monteverde, M; Tonissi, F | 1 |
| Al-Omary, FA; El-Messery, SM; El-Subbagh, HI; Hassan, GS | 1 |
| Baergen, RN; Boeck, M; Christos, P; Chuang, E; Cigler, T; Cobham, MV; Donovan, D; Jain, S; Lam, C; Lane, ME; Mittal, V; Moore, A; O'Loughlin, J; Rafii, S; Schneider, S; Swistel, A; Vahdat, LT; Ward, MM; Wiener, N | 1 |
| Ansén, S; Bass, AJ; Beer, DG; Brace, LE; Brambilla, C; Brambilla, E; Brustugun, OT; Cho, J; Clement, JH; Deng, X; Dutt, A; Eck, MJ; Gabler, F; Gray, NS; Greulich, H; Groen, H; Hammerman, PS; Hanna, M; Hatton, C; Haura, EB; Helland, A; Heuckmann, JM; Heynck, S; Janne, PA; Johnson, BE; Koker, M; Lawrence, MS; Leenders, F; Lim, SM; Lin, W; Lorimier, P; Meyerson, M; Moch, H; Onofrio, RC; Peifer, M; Petersen, I; Querings, S; Ramos, AH; Rauh, D; Salvesen, HB; Seidel, D; Sietsma, H; Simard, JR; Soltermann, A; Sos, ML; Stoelben, E; Thomas, RK; Timens, W; Tsao, MS; Winckler, W; Wolf, J; Wong, KK; Woods, BA; Xu, C; Zander, T; Zhang, J; Zhou, W | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Gangarajula, S; Ghosh, AK; Huang, X; Kulkarni, S; Pandey, S; Rao, KV; Tang, J; Xu, X | 1 |
| Gadher, SJ; Hajduch, M; Halada, P; Hrabakova, R; Kollareddy, M; Kovarova, H; Tyleckova, J | 1 |
| Chang, AY; Wang, M | 1 |
| Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S | 1 |
| Elmquist, WF; Mittapalli, RK; Sane, R | 1 |
| Broniscer, A; Gajjar, A; Kaste, SC; Kaufman, RA | 1 |
| Baker, JN; Baker, SD; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Huang, J; Kaste, SC; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panetta, JC; Stewart, CF; Wetmore, C | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Cai, J; Chen, J; Ji, M; Sun, M; Wang, P; Wu, X; Zong, X | 1 |
| Behera, R; Edwards, P; Guyett, PJ; Karver, CE; Mensa-Wilmot, K; Patel, G; Pollastri, MP; Roncal, NE; Sullenberger, C | 1 |
| de Wispelaere, M; LaCroix, AJ; Yang, PL | 1 |
| Mitrasinovic, PM | 1 |
| Ashworth, A; Campbell, J; Herrera-Abreu, MT; Knowles, MA; Pearson, A; Shnyder, SD; Turner, NC | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Bahare, RS; Khan, SA; Malik, S | 1 |
| Koutentis, PA; Manos, MJ; Mirallai, SI | 1 |
| Dai, B; Fang, B; Gao, W; Hofstetter, WL; Lu, H; Meng, J; Minna, J; Roth, JA; Swisher, SG; Wang, L; Wu, S | 1 |
| Barth, C; Massard, C; Vignot, S | 1 |
| Byagowi, S; Darabi, M; Fayezi, S; Mirshahvaladi, S; Sahmani, M | 1 |
| Baxter, RC; de Silva, HC; Lin, MZ; Martin, JL; Scott, CD | 1 |
| Ambrosini, G; de Stanchina, E; Musi, E; Schwartz, GK | 1 |
| Bessoff, K; Foderaro, JE; Huston, CD; Jumani, RS; Spangenberg, T; Ward, GE | 1 |
| Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y | 1 |
| Ballestrero, A; Bauer, I; Bruzzone, S; Damonte, P; Del Rio, A; Franceschi, C; Galeno, L; Grozio, A; Millo, E; Nencioni, A; Parenti, MD; Sociali, G | 1 |
| Carducci, MA; Chi, KN; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Kavsak, P; Kollmannsberger, CK; Mukherjee, SD; Siu, LL; Smith, DC; Spreafico, A; Sridhar, SS; Sukhai, MA; Takebe, N; Wang, L; Wong, TS | 1 |
| Cho, H; Gray, NS; Liu, S; Vetter, ML; Wang, J; Yang, PL; Zhang, J; Zhang, W; Zhang, Z | 1 |
| Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A | 1 |
| Ambudkar, SV; Chen, ZS; Kathawala, RJ; Patel, A; Sim, HM; Talele, TT; Wang, DS; Wang, YJ; Xu, RH; Zhang, H; Zhang, YK | 1 |
| Agarwal, SM; Chauhan, JS; Dhanda, SK; Raghava, GP; Singla, D | 1 |
| Abbagani, S; Banothu, J; Bavantula, R; Busi, S; Gali, R; Hnamte, S; Porika, M; Velpula, R | 1 |
| Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W | 1 |
| Bustos, D; Kirkpatrick, DS; Lin, E; Nicholes, K; Settleman, J; Song, Q; Stephan, JP; Wilson, C | 1 |
| Besson, T; Casagrande, AS; Désiré, L; Dubouilh-Benard, C; Foucourt, A; Hédou, D; Leblond, B; Loäec, N; Meijer, L | 1 |
| Jean-Claude, BJ; Larroque-Lombard, AL; Peyrard, L; Rachid, Z; Rao, S; Thauvin, C; Williams, C | 1 |
| Chow, JP; Hong, MJ; Li, J; Ma, HT; Mak, JP; Man, WY; Poon, RY | 1 |
| Arz, D; Blanz, J; Blasco, F; Caravatti, G; Desrayaud, S; Fairhurst, RA; Fritsch, C; Furet, P; Gerspacher, M; Guthy, DA; Imbach-Weese, P; Knapp, M; Luu, VH; Mah, R; Roehn-Carnemolla, E; Schnell, C; Wirth, J | 1 |
| Cui, Y; Gong, Y; Kang, X; Lu, P; Wang, Y; Xu, Z; Zhang, Q | 1 |
| Krop, IE; Lin, NU; Liu, P; Roberts, TM; Spangle, JM; Von, T; Wang, Q; Winer, EP; Zhao, JJ | 1 |
| Arteaga, CL; Bose, R; Button, B; Chu, D; Cidado, J; Cimino-Mathews, A; Cochran, RL; Cravero, K; Croessmann, S; Dalton, WB; Erlanger, B; Kavuri, SM; Konstantopoulos, K; Kyker-Snowman, K; Lauring, J; Manto, KM; Park, BH; Parsons, HA; Red Brewer, M; Rosen, DM; Wong, HY; Yankaskas, CL; Zabransky, DJ | 1 |
| Abad, S; Auladell, C; Beas-Zarate, C; Camins, A; Ettcheto, M; Folch, J; García, ML; Olloquequi, J; Petrov, D; Sánchez-López, E | 1 |
| Huang, G; Jia, W; Li, J; Liu, J; Liu, L; Miao, P; Song, S; Sun, X; Yan, H; Yang, H; Zhao, L; Zhao, X; Zhou, X | 1 |
| Chen, Y; Dong, Y; Jiang, Z; Li, Y; Pei, H; Peng, Y; Shao, T; Sun, Z; Tang, W; Wang, J; Yi, Z; Zhou, W | 1 |
| Liu, P; Xu, B; Zhang, C | 1 |
| Lang, B; Meng, LR; Shang, C | 1 |
| Akhtar, MJ; Ali, Z; Haider, MR; Khan, AA; Siddiqui, AA; Yar, MS | 1 |
| Amico, G; Baroni, D; Brandas, C; Moran, O | 1 |
| Almengló, C; Álvarez, E; González-Juanatey, JR; González-Peteiro, M; Mosquera-Garrote, N | 1 |
| Danzer, SC; Gross, C; MacLeod, MC; Tiwari, D; White, AR | 1 |
| Jain, S; Vaidya, A; Yadav, P; Yadav, R | 1 |
| Abramson, VG; Ayers, GD; Chen, SC; Mayer, IA; Richmond, A; Saleh, N; Yan, C; Yang, J | 1 |
19 review(s) available for thiazoles and quinazolines
| Article | Year |
|---|---|
The use of diacylglycerol kinase inhibitors for elucidating the roles of protein kinase C.
Topics: Animals; Blood Platelets; Diacylglycerol Kinase; Diglycerides; Enzyme Activation; Humans; Neutrophils; Phosphotransferases; Piperidines; Protein Kinase C; Pyrimidinones; Quinazolines; Quinazolinones; Rabbits; Receptors, Cell Surface; Second Messenger Systems; Thiazoles | 1990 |
Small molecular anti-cytokine agents.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Caspase Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytokines; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridazines; Pyridines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Succinates; Thiazoles; Tumor Necrosis Factor-alpha; Urea | 2006 |
Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Topics: Benzodioxoles; Clinical Trials, Phase I as Topic; Dasatinib; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Thiazoles | 2006 |
Src as a therapeutic target in men with prostate cancer and bone metastases.
Topics: Antineoplastic Agents; Benzodioxoles; Bone Neoplasms; Dasatinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Receptors, Androgen; src-Family Kinases; Thiazoles | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Aurora kinase inhibitors as anti-cancer therapy.
Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinase C; Aurora Kinases; Benzamides; Benzimidazoles; Cyclohexanecarboxylic Acids; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; Neoplasms; Organophosphates; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines; Thiazoles; Urea | 2010 |
Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.
Topics: Animals; Antifungal Agents; Clinical Trials as Topic; Drug Resistance, Fungal; Fungi; Humans; Microbial Sensitivity Tests; Mycoses; Nitriles; Pyridines; Quinazolines; Thiazoles; Triazoles | 2010 |
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines | 2010 |
[SRC kinases in tumor therapy].
Topics: Aniline Compounds; Benzodioxoles; Cell Physiological Phenomena; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; DNA Mutational Analysis; Drug Delivery Systems; Enzyme Activation; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2010 |
[Recent advances in the study of new antifungal lead compounds].
Topics: Antifungal Agents; Fungi; Heterocyclic Compounds; Humans; Lipopeptides; Molecular Structure; Mycoses; Nitriles; Plant Extracts; Plants, Medicinal; Pyridines; Quinazolines; Quinones; Structure-Activity Relationship; Thiazoles; Triazoles | 2010 |
Newer antifungal agents.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis, Invasive; Child; Clinical Trials as Topic; Half-Life; Humans; Lipopeptides; Nitriles; Pyridines; Quinazolines; Thiazoles; Triazoles | 2011 |
Current status of SRC inhibitors in solid tumor malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
An update on dual Src/Abl inhibitors.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2012 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
[Bone targeted therapies: new agents].
Topics: Aniline Compounds; Benzodioxoles; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Dasatinib; Diphosphonates; Humans; Molecular Targeted Therapy; Nitriles; Parathyroid Hormone-Related Protein; Pyrimidines; Quinazolines; Quinolines; RANK Ligand; Receptors, Chemokine; src-Family Kinases; Thiazoles; Transforming Growth Factor beta1 | 2013 |
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzamides; Benzodioxoles; Brain; Disease Models, Animal; Humans; Mice; Neurons; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; PrPC Proteins; Pyridines; Quinazolines; Receptor, Metabotropic Glutamate 5; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Synapses; Thiazoles | 2016 |
Caspase-3: A primary target for natural and synthetic compounds for cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Chalcone; Drug Screening Assays, Antitumor; Humans; Hydrazones; Indolequinones; Quinazolines; Quinazolinones; Structure-Activity Relationship; Thiazoles | 2021 |
8 trial(s) available for thiazoles and quinazolines
| Article | Year |
|---|---|
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Count; Cohort Studies; Dasatinib; Female; Hemangioblasts; Hematopoietic Stem Cells; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Thiazoles; Trastuzumab; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Follow-Up Studies; Glioma; Humans; Infant; Knee Joint; Magnetic Resonance Imaging; Male; Osteonecrosis; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiography; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Glioma; Humans; Male; Piperidines; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Collagen Type I; Dasatinib; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; src-Family Kinases; Taxoids; Thiazoles; Treatment Outcome | 2014 |
107 other study(ies) available for thiazoles and quinazolines
| Article | Year |
|---|---|
Influence of structural changes in the imidazolidine ring of clonidine on hypotensive activity.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Clonidine; Drug Evaluation, Preclinical; Heart Rate; Hypotension; Imidazoles; Male; Quinazolines; Rats; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Structure-Activity Relationship; Thiazoles | 1978 |
Synthesis and anticonvulsant properties of some novel quinazolone-thiosemicarbazone and 4-thiazolidone derivatives.
Topics: Animals; Anticonvulsants; Female; Male; Mice; Quinazolines; Thiazoles; Thiosemicarbazones | 1991 |
Studies on cardiotonic agents. VI. Synthesis of novel 4,5-dihydro-3(2H)-pyridazinone derivatives carrying some benzoheterocycles at the 6-position.
Topics: Animals; Cardiotonic Agents; Dogs; Imidazoles; Myocardial Contraction; Pyridazines; Quinazolines; Thiazoles; Thiophenes | 1991 |
Chemical structure and teratogenic properties. II. Synthesis and teratogenic activity in rabbits of some derivatives of phthalmide, isoindoline-1-one, 1,2-benzisothiazoline-3-one-1,1-dioxide and 4(3H)-quinazolinone.
Topics: Abnormalities, Drug-Induced; Acetamides; Animals; Female; Imides; Indoles; Pregnancy; Quinazolines; Rabbits; Succinimides; Thiazoles | 1972 |
Studi on siomycin. II. The composition and degradation products of siomycin A.
Topics: Acetaldehyde; Alanine; Amino Acids; Anti-Bacterial Agents; Butyrates; Carbon; Chemical Phenomena; Chemistry; Cysteine; Optical Rotatory Dispersion; Oxidation-Reduction; Propionates; Pyruvates; Quinazolines; Thiazoles; Threonine; Valine | 1969 |
Synthesis and antiallergy activity of 5-oxo-5H-thiazolo[2,3-b]quinazolinecarboxylic acids.
Topics: Animals; Bronchi; Chemical Phenomena; Chemistry; Hypersensitivity; Passive Cutaneous Anaphylaxis; Quinazolines; Rats; Thiazoles | 1983 |
Possible relationship between glycosphingolipids and the formation of metastasis in certain human experimental tumors.
Topics: Animals; Carcinoma, Squamous Cell; Chick Embryo; Gangliosides; Glycosphingolipids; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Quinazolines; Sarcoma; Thiazoles | 1980 |
Synthesis and anticonvulsant properties of some novel quinazolinone thiazolidine and 4-thiazolidone derivatives.
Topics: Animals; Anticonvulsants; Female; Male; Mice; Pentylenetetrazole; Quinazolines; Seizures; Spectrophotometry, Infrared; Thiazoles | 1993 |
Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Binding Sites; Brain; Chromatography, Ion Exchange; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Guinea Pigs; Isoenzymes; Isoproterenol; Kinetics; Macrophages, Peritoneal; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrrolidinones; Quinazolines; Rats; Regression Analysis; Rolipram; Stereoisomerism; Thiazoles; Tritium | 1996 |
3-[4-(3,4-Dimethylphenyl)-1,3-thiazol-2-yl]-2-(2-hydroxyphenyl)-1,2,3,4- tetrahydroquinazolin-4-one.
Topics: Crystallography, X-Ray; Hydrogen Bonding; Quinazolines; Thiazoles | 2000 |
Synthesis and evaluation of some new fluorinated hydroquinazoline derivatives as antifungal agents.
Topics: Antifungal Agents; Aspergillus flavus; Aspergillus ochraceus; Candida albicans; Fluorides; Microbial Sensitivity Tests; Molecular Structure; Penicillium chrysogenum; Quinazolines; Thiazoles | 2000 |
Synthesis and antifungal activity of novel pyrano[2',3':4,5]thiazolo[2,3-b]quinazolines, pyrido[2',3':4,5]thiazolo[2,3-b]quinazolines and pyrazolo[2',3':4,5]thiazolo[2,3-b]quinazolines.
Topics: Antifungal Agents; Aspergillus flavus; Aspergillus ochraceus; Candida albicans; Microbial Sensitivity Tests; Molecular Structure; Penicillium chrysogenum; Pyrans; Pyrazoles; Pyridines; Quinazolines; Thiazoles | 2000 |
Synthesis and immunomodulating activity of 5H-thiazolo[2,3-b]quinazolin-3(2H)-one.
Topics: Animals; Female; Immunosuppressive Agents; Mice; Mice, Inbred C3H; Quinazolines; Thiazoles | 1987 |
Synthesis of certain pyrimido[2,1-b]benzothiazole and benzothiazolo[2,3-b]quinazoline derivatives for in vitro antitumor and antiviral activities.
Topics: Antineoplastic Agents; Antiviral Agents; Chemical Phenomena; Chemistry, Physical; Drug Screening Assays, Antitumor; Herpesvirus 1, Human; Humans; Microbial Sensitivity Tests; Pyrimidines; Quinazolines; Thiazoles; Tumor Cells, Cultured | 2000 |
Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension.
Topics: Cell Nucleus; Diacylglycerol Kinase; Diglycerides; DNA; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; HeLa Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Luciferases; Nuclear Proteins; Oxygen; Phosphatidic Acids; Phospholipids; Piperidines; Plasmids; Pyrimidinones; Quinazolines; Quinazolinones; Recombinant Proteins; Signal Transduction; Thiazoles; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection | 2001 |
In vitro activities of four novel triazoles against Scedosporium spp.
Topics: Antifungal Agents; Humans; Microbial Sensitivity Tests; Pyrimidines; Quinazolines; Scedosporium; Thiazoles; Triazoles; Voriconazole | 2001 |
II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
Topics: Animals; Antineoplastic Agents; Benzoxazoles; Drug Screening Assays, Antitumor; Mice; Neoplasm Transplantation; Propionates; Pyrazines; Pyridines; Quinazolines; Quinolines; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Triazines; Tumor Cells, Cultured | 2002 |
Effect of novel modulators of protein kinase C activity upon chemotherapy-induced differentiation and apoptosis in myeloid leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; CD11c Antigen; CD4 Antigens; Cell Cycle; Cell Differentiation; Diacylglycerol Kinase; Enzyme Activators; Enzyme Inhibitors; Farnesol; Flow Cytometry; Genes, fos; Genes, jun; Humans; Immunoblotting; Isoenzymes; Leukemia, Myeloid; Naphthalenes; Oncogene Protein p21(ras); Piperidines; Protein Kinase C; Pyrimidinones; Quinazolines; Quinazolinones; Sulfonamides; Thiazoles; Triazoles; Tumor Cells, Cultured | 2002 |
Synthesis and in vitro antibacterial evaluation of novel imidazo[2',1':5,1]-1,2,4-triazolo[4,3-c]-quinazoline derivatives of 5-thioxo-1, 2, 4-triazole, 4-oxothiazolidine, and their open-chain counterparts.
Topics: Anti-Bacterial Agents; Colony Count, Microbial; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinazolines; Quinazolinones; Structure-Activity Relationship; Thiazoles; Triazoles | 2003 |
New drugs 04, part 1.
Topics: Adalimumab; Alefacept; alpha-Galactosidase; Anisoles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Antiprotozoal Agents; Antirheumatic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Approval; Drug Therapy; Fabry Disease; Gefitinib; Humans; Iduronidase; Indoles; Isoenzymes; Lentigo; Lung Neoplasms; Migraine Disorders; Mucopolysaccharidosis I; Nitro Compounds; Patient Education as Topic; Propylamines; Psoriasis; Pyrrolidines; Quinazolines; Recombinant Fusion Proteins; Serotonin Receptor Agonists; Thiazoles; Tryptamines | 2004 |
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Topics: Amphotericin B; Antifungal Agents; Drug Interactions; Drug Resistance, Fungal; Fusarium; Humans; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Pyrimidines; Quinazolines; Sensitivity and Specificity; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2004 |
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Hypoxia; Mammary Neoplasms, Animal; Mice; Mice, SCID; Neoplasm Transplantation; Phosphorylation; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab | 2004 |
Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cell Line, Tumor; Coloring Agents; Dose-Response Relationship, Drug; Flow Cytometry; G2 Phase; Histones; Humans; In Situ Nick-End Labeling; L-Lactate Dehydrogenase; Male; Mitosis; Models, Chemical; Plant Extracts; Ploidies; Prostatic Neoplasms; Quinazolines; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Cell growth after withdrawal of gefitinib ("Iressa", ZD1839) in human lung cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Coloring Agents; Dose-Response Relationship, Drug; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
In vitro antifungal susceptibility of Cryptococcus gattii.
Topics: Antifungal Agents; Cryptococcus; Cryptococcus neoformans; Humans; Microbial Sensitivity Tests; Quinazolines; Thiazoles; Triazoles | 2004 |
Synthesis and evaluation of some novel quinazolinone derivatives as diuretic agents.
Topics: Animals; Diuretics; Lethal Dose 50; Quinazolines; Rats; Structure-Activity Relationship; Thiadiazoles; Thiazoles | 2004 |
The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Body Temperature; Conditioning, Psychological; Excitatory Amino Acid Antagonists; Male; Mice; Motor Activity; Pyridines; Quinazolines; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles | 2005 |
CH...O and CH...N hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor.
Topics: Drug Design; Glycogen Synthase Kinase 3; Hydrogen Bonding; Isomerism; Ligands; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Thiazoles | 2005 |
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoblotting; Inhibitory Concentration 50; Lung Neoplasms; Models, Statistical; Polymerase Chain Reaction; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; Tetrazolium Salts; Thiazoles | 2005 |
Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic.
Topics: Algorithms; Analgesics; Animals; Behavior, Animal; Benzothiazoles; Brain; Cimetidine; Dose-Response Relationship, Drug; Histamine H2 Antagonists; Injections, Intraventricular; Male; Mice; Molecular Structure; Pain; Pain Measurement; Phenoxypropanolamines; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors; Triazoles | 2005 |
Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases.
Topics: Biotin; Cell Proliferation; Cells, Cultured; Chemistry, Pharmaceutical; Drug Design; Endothelial Cells; Endothelium, Vascular; Humans; Hydrocarbons, Brominated; Inhibitory Concentration 50; Ligands; Light; Models, Chemical; Protein Binding; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Spectrophotometry, Ultraviolet; Thiazoles; Time Factors; Ultraviolet Rays; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Synthesis of the PPARbeta/delta-selective agonist GW501516 and C4-thiazole-substituted analogs.
Topics: Catalysis; Cell Line; Chemistry, Pharmaceutical; Drug Design; Genes, Reporter; Genetic Techniques; Globins; HeLa Cells; Humans; Hydroxybenzoates; Ligands; Lipids; Models, Chemical; Palladium; PPAR delta; PPAR-beta; Promoter Regions, Genetic; Quinazolines; Thiazoles; Time Factors; Transcription, Genetic; Transcriptional Activation | 2006 |
Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line.
Topics: Antimitotic Agents; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA; DNA Primers; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Genistein; Histones; Humans; Isoflavones; Kinesins; Male; Models, Statistical; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Spindle Apparatus; Tetrazolium Salts; Thiazoles | 2006 |
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinases; Cell Line, Tumor; Histones; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasm Transplantation; Organophosphates; Phosphoproteins; Prodrugs; Protein Serine-Threonine Kinases; Quantum Theory; Quinazolines; Structure-Activity Relationship; Thiazoles; Xenograft Model Antitumor Assays | 2006 |
Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Transitional Cell; Cyclooxygenase Inhibitors; Gefitinib; Male; Meloxicam; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred F344; Thiazines; Thiazoles; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Thiazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cell Membrane; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Immunoblotting; Iodides; Molecular Structure; Mutant Proteins; Mutation; Piperazines; Protein Processing, Post-Translational; Quinazolines; Styrenes; Thiazoles | 2006 |
Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3.
Topics: Adenosine Triphosphate; Binding Sites; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Hydrogen Bonding; Microwaves; Models, Molecular; Quinazolines; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2006 |
In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Quinazolines; Thiazoles; Triazoles | 2006 |
Impact of genetic diagnostics on drug development strategy.
Topics: Antineoplastic Agents; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Gefitinib; Genetic Testing; Humans; Neoplasms; Pharmacogenetics; Pyrimidines; Quinazolines; Thiazoles | 2006 |
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; ErbB Receptors; Fluorine; Gefitinib; Humans; Inhibitory Concentration 50; Mice; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Structure-Activity Relationship; Thiazoles; Xenograft Model Antitumor Assays | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Topics: Amphotericin B; Antifungal Agents; Candida; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Ketoconazole; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Naphthalenes; Peptides, Cyclic; Pseudallescheria; Pyrimidines; Quality Control; Quinazolines; Scedosporium; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2006 |
Anaerobic NADH-fumarate reductase system is predominant in the respiratory chain of Echinococcus multilocularis, providing a novel target for the chemotherapy of alveolar echinococcosis.
Topics: Anaerobiosis; Animals; Echinococcosis, Hepatic; Echinococcus multilocularis; Electron Transport; Enzyme Inhibitors; Mitochondria; Nitro Compounds; Oxidoreductases Acting on CH-CH Group Donors; Quinazolines; Rotenone; Thiazoles; Ubiquinone | 2008 |
Discovery of a potent and selective aurora kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Aurora Kinases; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Structure-Activity Relationship; Thiazoles | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Fluorescent Dyes; Humans; Indicators and Reagents; Multidrug Resistance-Associated Proteins; Oncogene Protein v-akt; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; RNA Interference; Tetrazolium Salts; Thiazoles | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; src-Family Kinases; Thiazoles | 2010 |
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dasatinib; Humans; Lapatinib; Limit of Detection; Mass Spectrometry; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sensitivity and Specificity; Thiazoles | 2009 |
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells.
Topics: Animals; Animals, Newborn; Apoptosis; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Green Fluorescent Proteins; Humans; Mutation; Nerve Tissue Proteins; Neurons; Oxidative Stress; Quinazolines; Signal Transduction; Stem Cells; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Tyrphostins | 2010 |
Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Biotransformation; Blotting, Western; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Coloring Agents; Extracellular Signal-Regulated MAP Kinases; Fas Ligand Protein; Humans; Melanoma, Experimental; NF-kappa B; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Plant Extracts; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Tetrazolium Salts; Thiazoles; Ubiquitin | 2010 |
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, p53; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Pyrazoles; Quinazolines; Temozolomide; Tetrazolium Salts; Thiazoles | 2010 |
Synthesis and antimycobacterial activity of azetidine-, quinazoline-, and triazolo-thiadiazole-containing pyrazines.
Topics: Antitubercular Agents; Azetidines; Cell Wall; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Permeability; Pyrazines; Quinazolines; Structure-Activity Relationship; Thiadiazoles; Thiazoles | 2010 |
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Response to combined molecular targeting: defining the role of P-STAT3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).
Topics: Dyrk Kinases; Enzyme Activation; Enzyme Inhibitors; Inhibitory Concentration 50; Isoenzymes; Models, Molecular; Molecular Structure; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Small Molecule Libraries; Substrate Specificity; Thiazoles | 2011 |
Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery.
Topics: Animals; Axons; Coumarins; Drug Delivery Systems; ErbB Receptors; Female; Lactic Acid; Microscopy, Fluorescence; Microspheres; Models, Chemical; Nanospheres; Nerve Regeneration; Neurons; Optic Nerve; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Sprague-Dawley; Thiazoles; Tyrphostins | 2011 |
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Death; Cell Line, Transformed; Cell Transformation, Neoplastic; Checkpoint Kinase 1; Dasatinib; Female; Fibroblasts; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Protease Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-fyn; Proto-Oncogene Proteins c-yes; Pyrimidines; Quinazolines; Radiation Tolerance; src-Family Kinases; Thiazoles | 2011 |
Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.
Topics: Aminacrine; Bacterial Proteins; Benzamides; Cell Line; Cell Membrane; Chlorides; Ciclopirox; Cold Temperature; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Gene Expression Profiling; Gene Expression Regulation; Humans; Hydroxamic Acids; Luminescent Proteins; Mutation; Piperazines; Protein Transport; Pyridones; Quinazolines; Thiazoles; Vorinostat | 2011 |
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Taxoids; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Substituted thiazoles V. synthesis and antitumor activity of novel thiazolo[2,3-b]quinazoline and pyrido[4,3-d]thiazolo[3,2-a]pyrimidine analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Pyrimidines; Quinazolines; Thiazoles | 2012 |
New drugs 2012 part I.
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzazepines; Benzimidazoles; Benzofurans; Ceftaroline; Cephalosporins; Cyclopropanes; Drug Approval; Drug Combinations; Humans; Imidazoles; Indoles; Isoindoles; Linagliptin; Lurasidone Hydrochloride; Macrolides; Oxadiazoles; Piperazines; Proline; Purines; Quinazolines; Thiazoles; United States; Vilazodone Hydrochloride | 2012 |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Dasatinib; Discoidin Domain Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; src-Family Kinases; Thiazoles | 2011 |
Structure-based design, synthesis, and biological evaluation of dihydroquinazoline-derived potent β-secretase inhibitors.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Catalytic Domain; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Pyrazoles; Quinazolines; Structure-Activity Relationship; Thiazoles | 2012 |
Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Antineoplastic Agents; Apoptosis; Aurora Kinases; Benzamides; Drug Resistance, Neoplasm; GTP-Binding Proteins; HCT116 Cells; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinazolines; Thiazoles; Tumor Suppressor Protein p53 | 2013 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Brain; Cell Line; Dasatinib; Dogs; Drug Delivery Systems; Emulsions; Erlotinib Hydrochloride; Humans; Mice; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Solubility; Tetrahydroisoquinolines; Thiazoles | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
Topics: Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Design; HCT116 Cells; Humans; Inhibitory Concentration 50; K562 Cells; Models, Chemical; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; src-Family Kinases; Thiazoles; U937 Cells | 2013 |
Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Coloring Agents; Drug Design; Drug Discovery; ErbB Receptors; Humans; Indicators and Reagents; Lapatinib; Morpholines; Neglected Diseases; Phosphotransferases; Quinazolines; Structure-Activity Relationship; Tetrazolium Salts; Thiazoles; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2013 |
The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.
Topics: Antibodies, Monoclonal; Benzodioxoles; Blotting, Northern; Blotting, Western; Cell Survival; Dasatinib; Dengue Virus; Dimethyl Sulfoxide; DNA Primers; HEK293 Cells; Humans; Mycophenolic Acid; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Pyrimidines; Quinazolines; Replicon; RNA Interference; RNA, Viral; Thiazoles; Virus Replication | 2013 |
Inhibitory activity against epidermal growth factor receptor (EGFR) based on single point mutations of active site residues.
Topics: Catalytic Domain; ErbB Receptors; Humans; Lapatinib; Molecular Structure; Point Mutation; Protein Engineering; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Structure-Activity Relationship; Thiazoles | 2014 |
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
Topics: Animals; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gefitinib; Heterografts; High-Throughput Screening Assays; Humans; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2013 |
Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Disease Models, Animal; Drug Design; Electroshock; Injections, Intraperitoneal; Mice; Molecular Structure; Quinazolines; Rats; Rats, Wistar; Seizures; Thiazoles; Thioamides | 2013 |
One-step conversion of 2-amino-N'-arylbenzamidines into 3-aryl-4-imino-3,4-dihydroquinazoline-2-carbonitriles using 4,5-dichloro-1,2,3-dithiazolium chloride.
Topics: Imines; Molecular Structure; Nitriles; Quinazolines; Thiazoles | 2013 |
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor Binding Protein 2; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Transcriptional regulation of Δ6-desaturase by peroxisome proliferative-activated receptor δ agonist in human pancreatic cancer cells: role of MEK/ERK1/2 pathway.
Topics: Cell Line, Tumor; ErbB Receptors; Fatty Acid Desaturases; Flavonoids; Gene Expression Regulation, Enzymologic; Humans; MAP Kinase Signaling System; Pancreatic Neoplasms; PPAR delta; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Neoplasm; Thiazoles; Tyrphostins | 2013 |
Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thiazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Silencing; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Melanoma; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Pyrroles; Quinazolines; RNA Interference; Signal Transduction; Thiazoles; Tumor Burden; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box.
Topics: Antiprotozoal Agents; Cryptosporidium parvum; Drug Repositioning; Humans; Hydroxyquinolines; Nitro Compounds; Quinazolines; Thiazoles; Toxoplasma | 2014 |
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Discovery of novel and selective SIRT6 inhibitors.
Topics: Acetylation; Animals; Cell Line; Computer Simulation; Furans; Glucose; Glucose Transporter Type 1; Histone Deacetylase Inhibitors; Histones; Humans; Models, Molecular; Protein Binding; Pyridines; Pyrimidines; Quinazolines; Rats; Salicylates; Sirtuins; Structure-Activity Relationship; Thiazoles; Tumor Necrosis Factor-alpha; Up-Regulation | 2014 |
Fluorescent visualization of Src by using dasatinib-BODIPY.
Topics: Animals; Benzodioxoles; Boron Compounds; Cell Line; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Fluorescence; Humans; Mice; Microscopy, Fluorescence; Molecular Probes; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; Structure-Activity Relationship; Thiazoles | 2014 |
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Neoplasm Proteins; Oncogene Proteins v-erbB; Paclitaxel; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Thiazoles | 2014 |
QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.
Topics: Drug Design; ErbB Receptors; Humans; Models, Biological; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quantitative Structure-Activity Relationship; Quinazolines; Thiazoles | 2014 |
Indolylmethylene benzo[h]thiazolo[2,3-b]quinazolinones: synthesis, characterization and evaluation of anticancer and antimicrobial activities.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Aspergillus; Candida; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Klebsiella pneumoniae; MCF-7 Cells; Microbial Sensitivity Tests; Molecular Conformation; Pseudomonas aeruginosa; Quinazolines; Staphylococcus; Structure-Activity Relationship; Thiazoles | 2014 |
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles | 2014 |
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mutation; Pyrimidines; Quinazolines; Signal Transduction; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.
Topics: Chemistry Techniques, Synthetic; Drug Design; Dyrk Kinases; Humans; Inhibitory Concentration 50; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Structure-Activity Relationship; Thiazoles | 2014 |
Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
Topics: Animals; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Drug Design; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; src-Family Kinases; Thiazoles; Transplantation, Heterologous | 2015 |
Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Carcinoma; Cell Cycle Proteins; Cyclohexanecarboxylic Acids; Drug Synergism; Female; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Molecular Targeted Therapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Organophosphates; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Quinazolines; Thiazoles; Tumor Cells, Cultured | 2015 |
Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Topics: Animals; Caco-2 Cells; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mice, Nude; Models, Molecular; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Thiazoles | 2015 |
[Bufalin reverses hepatocyte growth factor-induced resistance to afatinib in H1975 lung cancer cells].
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Cadherins; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Hepatocyte Growth Factor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Quinazolines; Signal Transduction; Tetrazolium Salts; Thiazoles | 2015 |
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice, Knockout; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Flow Cytometry; Gene Targeting; HEK293 Cells; Humans; Immunoblotting; Lapatinib; Mutation, Missense; Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Thiazoles | 2015 |
Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxycholesterols; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Pyridines; Quinazolines; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Thiazoles; Triterpenes; Xenograft Model Antitumor Assays | 2016 |
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Colony-Forming Units Assay; Drug Design; Drug Discovery; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Rats, Sprague-Dawley; Signal Transduction; Stress Fibers; Thiazoles; Wound Healing | 2016 |
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays | 2016 |
Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.
Topics: AC133 Antigen; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Diamines; Drug Resistance, Neoplasm; Drug Synergism; Endometrial Neoplasms; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Receptors, Notch; Signal Transduction; Thiazoles; Tyrphostins; Xenograft Model Antitumor Assays | 2018 |
Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor.
Topics: Animals; Antioxidants; Biphenyl Compounds; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Free Radicals; Hypoglycemic Agents; Molecular Docking Simulation; Picrates; Quinazolines; Rats, Wistar; Thiazoles | 2017 |
Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Topics: Aminopyridines; Benzamides; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Gene Expression Regulation; HEK293 Cells; Humans; Indoles; Mutant Proteins; Mutation; Quinazolines; Thiazoles | 2019 |
Edoxaban's contribution to key endothelial cell functions.
Topics: Cell Adhesion; Cells, Cultured; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes, Mononuclear; Pyridines; Pyrroles; Quinazolines; Thiazoles; Wound Healing | 2020 |
PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes.
Topics: Adenine; Animals; Cerebral Cortex; Class I Phosphatidylinositol 3-Kinases; Epilepsy; Female; Hippocampus; Male; Megalencephaly; Mice; Neurons; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Seizures; Thiazoles | 2020 |
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Granulocytes; Humans; Immune Checkpoint Inhibitors; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome; Triazines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |